English 
Español
Development and validation of a mass spectrometric method to determine the identity of rituximab based on its microheterogeneity profile. IN PRESS
Related Articles
-
UDIBI
Published: February 27, 2023 Discovery and Optimization of Neutralizing SARS-CoV-2 Antibodies Using ALTHEA Gold Plus Libraries™ More information
-
-
UDIBI
Mycobacterium tuberculosis Catalase Inhibits the Formation of Mast Cell Extracellular Traps. SHOW MORE
-
UDIBI
Determination of Peptide Profile Consistency and Safety of Collagen Hydrolysates as Quality Attributes. SHOW MORE
-
UDIBI
Validation of an ADCC assay using human primary natural killer cells to evaluate biotherapeutic products bearing an Fc región....
-
UDIBI
Published: September 6, 2022 In Vitro and In Vivo Characterization of a Broadly Neutralizing Anti-SARS-CoV-2 Antibody Isolated from a...
-
UDIBI
Identity Profiling of Complex Mixtures of Peptide Products by Structural and Mass Mobility Orthogonal Analysis. SHOW MORE
-
UDIBI
Published: September 20, 2019 Validation of a Cell Proliferation Assay to Assess the Potency of a Dialyzable Leukocyte Extract...
